LLY

1,014.52

-1.97%↓

JNJ

202.07

-1.79%↓

ABBV

228.32

-0.87%↓

UNH

331.69

-2.2%↓

AZN

90.21

-0.75%↓

LLY

1,014.52

-1.97%↓

JNJ

202.07

-1.79%↓

ABBV

228.32

-0.87%↓

UNH

331.69

-2.2%↓

AZN

90.21

-0.75%↓

LLY

1,014.52

-1.97%↓

JNJ

202.07

-1.79%↓

ABBV

228.32

-0.87%↓

UNH

331.69

-2.2%↓

AZN

90.21

-0.75%↓

LLY

1,014.52

-1.97%↓

JNJ

202.07

-1.79%↓

ABBV

228.32

-0.87%↓

UNH

331.69

-2.2%↓

AZN

90.21

-0.75%↓

LLY

1,014.52

-1.97%↓

JNJ

202.07

-1.79%↓

ABBV

228.32

-0.87%↓

UNH

331.69

-2.2%↓

AZN

90.21

-0.75%↓

Search

VistaGen Therapeutics Inc

Avatud

4.08 11.78

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.74

Max

4.09

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+233.33% upside

VistaGen Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. dets 2025, 23:21 UTC

Tulu
Omandamised, ülevõtmised, äriostud

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3. dets 2025, 23:14 UTC

Omandamised, ülevõtmised, äriostud

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3. dets 2025, 22:01 UTC

Suurimad hinnamuutused turgudel

Costco Wholesale Reports Higher Monthly Sales

3. dets 2025, 21:38 UTC

Tulu

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3. dets 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3. dets 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. dets 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3. dets 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3. dets 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3. dets 2025, 23:10 UTC

Tulu

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3. dets 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3. dets 2025, 23:06 UTC

Omandamised, ülevõtmised, äriostud

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3. dets 2025, 22:59 UTC

Omandamised, ülevõtmised, äriostud

EQB to Buy PC Financial From Loblaw for About $573.5M

3. dets 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3. dets 2025, 22:20 UTC

Tulu

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3. dets 2025, 22:19 UTC

Tulu

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3. dets 2025, 22:17 UTC

Tulu

Salesforce Working to Add Voice to Agentforce, CEO Says

3. dets 2025, 22:16 UTC

Tulu

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3. dets 2025, 22:15 UTC

Tulu

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3. dets 2025, 22:10 UTC

Omandamised, ülevõtmised, äriostud

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3. dets 2025, 22:09 UTC

Omandamised, ülevõtmised, äriostud

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3. dets 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3. dets 2025, 21:49 UTC

Tulu

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3. dets 2025, 21:23 UTC

Tulu

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3. dets 2025, 21:19 UTC

Tulu

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3. dets 2025, 21:06 UTC

Tulu

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3. dets 2025, 21:04 UTC

Tulu

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3. dets 2025, 21:04 UTC

Tulu

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3. dets 2025, 21:03 UTC

Tulu

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Võrdlus sarnastega

Hinnamuutus

VistaGen Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

233.33% tõus

12 kuu keskmine prognoos

Keskmine 12 USD  233.33%

Kõrge 12 USD

Madal 12 USD

Põhineb 3 Wall Streeti analüütiku instrumendi VistaGen Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

3

Osta

0

Hoia

0

Müü

Finantsandmed

$

help-icon Live chat